JP2022516974A5 - - Google Patents
Info
- Publication number
- JP2022516974A5 JP2022516974A5 JP2021539935A JP2021539935A JP2022516974A5 JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5 JP 2021539935 A JP2021539935 A JP 2021539935A JP 2021539935 A JP2021539935 A JP 2021539935A JP 2022516974 A5 JP2022516974 A5 JP 2022516974A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059887A JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790326P | 2019-01-09 | 2019-01-09 | |
| US62/790,326 | 2019-01-09 | ||
| PCT/US2020/012647 WO2020146440A1 (en) | 2019-01-09 | 2020-01-08 | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Division JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516974A JP2022516974A (ja) | 2022-03-03 |
| JPWO2020146440A5 JPWO2020146440A5 (https=) | 2023-01-24 |
| JP2022516974A5 true JP2022516974A5 (https=) | 2023-01-24 |
| JP7467479B2 JP7467479B2 (ja) | 2024-04-15 |
Family
ID=69500830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539935A Active JP7467479B2 (ja) | 2019-01-09 | 2020-01-08 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059887A Pending JP2024081769A (ja) | 2019-01-09 | 2024-04-03 | 多発性骨髄腫の治療における抗増殖化合物及び第２の活性薬剤とそれらの併用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11660297B2 (https=) |
| EP (2) | EP4461370A3 (https=) |
| JP (2) | JP7467479B2 (https=) |
| KR (1) | KR20210126011A (https=) |
| CN (3) | CN114404596A (https=) |
| AU (1) | AU2020205643C1 (https=) |
| CA (1) | CA3125753A1 (https=) |
| DK (1) | DK3908281T3 (https=) |
| EA (1) | EA202191903A1 (https=) |
| ES (1) | ES2995189T3 (https=) |
| FI (1) | FI3908281T3 (https=) |
| HR (1) | HRP20241309T1 (https=) |
| HU (1) | HUE068895T2 (https=) |
| IL (1) | IL284671B2 (https=) |
| LT (1) | LT3908281T (https=) |
| MX (2) | MX2021008294A (https=) |
| PL (1) | PL3908281T3 (https=) |
| PT (1) | PT3908281T (https=) |
| RS (1) | RS66066B1 (https=) |
| SG (1) | SG11202107413YA (https=) |
| SI (1) | SI3908281T1 (https=) |
| SM (1) | SMT202400388T1 (https=) |
| WO (1) | WO2020146440A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117838695A (zh) * | 2018-04-13 | 2024-04-09 | 住友制药肿瘤公司 | 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂 |
| WO2020146440A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
| AU2020206692B2 (en) * | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| MX2023009858A (es) * | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| EP4347037A1 (en) | 2021-05-27 | 2024-04-10 | Celgene Corporation | Methods of treating multiple myeloma using combination therapy |
| EP4370127A2 (en) * | 2021-07-12 | 2024-05-22 | Quteba Ebrahem | A method of treating cancer or a blood disorder |
| CN116496246A (zh) * | 2022-01-18 | 2023-07-28 | 中国药科大学 | 异吲哚啉类化合物、制备方法、药物组合物和应用 |
| CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
| CN119015299A (zh) * | 2024-08-21 | 2024-11-26 | 中国医学科学院肿瘤医院 | 西奈芬净在治疗癌症中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2956550A1 (en) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| EA202092830A1 (ru) * | 2018-05-23 | 2021-04-08 | Селджин Корпорейшн | Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения |
| WO2020146440A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
-
2020
- 2020-01-08 WO PCT/US2020/012647 patent/WO2020146440A1/en not_active Ceased
- 2020-01-08 ES ES20704117T patent/ES2995189T3/es active Active
- 2020-01-08 CN CN202210009586.2A patent/CN114404596A/zh active Pending
- 2020-01-08 US US16/737,710 patent/US11660297B2/en active Active
- 2020-01-08 CA CA3125753A patent/CA3125753A1/en active Pending
- 2020-01-08 EP EP24191518.0A patent/EP4461370A3/en active Pending
- 2020-01-08 JP JP2021539935A patent/JP7467479B2/ja active Active
- 2020-01-08 AU AU2020205643A patent/AU2020205643C1/en active Active
- 2020-01-08 DK DK20704117.9T patent/DK3908281T3/da active
- 2020-01-08 PT PT207041179T patent/PT3908281T/pt unknown
- 2020-01-08 IL IL284671A patent/IL284671B2/en unknown
- 2020-01-08 EP EP20704117.9A patent/EP3908281B9/en active Active
- 2020-01-08 RS RS20241127A patent/RS66066B1/sr unknown
- 2020-01-08 LT LTEPPCT/US2020/012647T patent/LT3908281T/lt unknown
- 2020-01-08 HR HRP20241309TT patent/HRP20241309T1/hr unknown
- 2020-01-08 SM SM20240388T patent/SMT202400388T1/it unknown
- 2020-01-08 PL PL20704117.9T patent/PL3908281T3/pl unknown
- 2020-01-08 MX MX2021008294A patent/MX2021008294A/es unknown
- 2020-01-08 EA EA202191903A patent/EA202191903A1/ru unknown
- 2020-01-08 KR KR1020217025057A patent/KR20210126011A/ko not_active Ceased
- 2020-01-08 SI SI202130207T patent/SI3908281T1/sl unknown
- 2020-01-08 CN CN202080018980.1A patent/CN113543786A/zh active Pending
- 2020-01-08 SG SG11202107413YA patent/SG11202107413YA/en unknown
- 2020-01-08 CN CN202410171019.6A patent/CN118178417A/zh active Pending
- 2020-01-08 HU HUE20704117A patent/HUE068895T2/hu unknown
- 2020-01-08 FI FIEP20704117.9T patent/FI3908281T3/fi active
-
2021
- 2021-07-08 MX MX2024008439A patent/MX2024008439A/es unknown
-
2023
- 2023-04-25 US US18/139,151 patent/US12186311B2/en active Active
-
2024
- 2024-04-03 JP JP2024059887A patent/JP2024081769A/ja active Pending
- 2024-11-21 US US18/955,085 patent/US20250082629A1/en active Pending